Literature DB >> 6136413

Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.

P Dayer, L Balant, A Küpfer, F Courvoisier, J Fabre.   

Abstract

The oxidative metabolism of bufuralol is under the same genetic control as that of debrisoquine and sparteine. 154 fasting volunteers received a 30 mg tablet of bufuralol and a blood sample was taken 3 h later. In poor metabolizers (8% of the sample) the plasma bufuralol concentrations were very high and the metabolite concentrations were low. The genetic oxidative status is a major source of interindividual variation in the plasma concentration of drugs that undergo oxidative metabolism.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6136413     DOI: 10.1007/bf00607090

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

2.  High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation.

Authors:  G Alvan; C von Bahr; P Seidemann; F Sjöqvist
Journal:  Lancet       Date:  1982-02-06       Impact factor: 79.321

3.  Genetically determined impaired drug sulphoxidation.

Authors:  R H Waring; S C Mitchell; J R Idle; R L Smith
Journal:  Lancet       Date:  1981-04-04       Impact factor: 79.321

4.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

5.  The genetic control of bufuralol metabolism in man.

Authors:  P Dayer; L Balant; F Courvoisier; A Kupfer; A Kubli; A Gorgia; J Fabre
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

6.  E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

Authors:  B Mellström; L Bertilsson; J Säwe; H U Schulz; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine.

Authors:  I Kitchen; J Tremblay; J André; L G Dring; J R Idle; R L Smith; R T Williams
Journal:  Xenobiotica       Date:  1979-07       Impact factor: 1.908

9.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.

Authors:  R R Shah; N S Oates; J R Idle; R L Smith; J D Lockhart
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30

10.  Metabolite cumulation during long-term oral encainide administration.

Authors:  R E Kates; D C Harrison; R A Winkle
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

View more
  9 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.

Authors:  P Dayer; T Leemann; A Marmy; J Rosenthaler
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 3.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 4.  Oxidation phenotype and the metabolism and action of beta-blockers.

Authors:  M S Lennard
Journal:  Klin Wochenschr       Date:  1985-04-01

5.  Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).

Authors:  J Pressacco; R Muller; W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Variability of plasma drug concentrations: some observations.

Authors:  D B Jack; M R Wilkins; M J Kendall; P E Hall
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.

Authors:  P Dayer; L Balant; A Kupfer; R Striberni; T Leemann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 8.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

9.  Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.

Authors:  P Dayer; T Leemann; A Küpfer; T Kronbach; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.